beeldscherm schreef op 7 november 2017 13:48:
BioCryst Reports Third Quarter 2017 Financial Results
..
The net loss for the third quarter of 2017 was $15.1 million, or $0.18 per share, compared to a net loss of $11 .5 million, or
$0.16 per share, for the third quarter 2016
oeps ook een concurrent voor Pharming op de HAE markt.nou infeite toch niet..
"Now that we have completed our end of Phase 2 regulatory interactions with the FDA and EMA and have agreement on the
requirements for marketing authorization applications of BCX7353, we are focused on executing the Phase 3 program to
support NDA and MAA filings in 2019," said Jon P. Stonehouse, President & Chief Executive Officer. "We expect to start the
single required Phase 3 efficacy and the long-term safety trials in first quarter 2018."
mocht alles goed gaan PAS in 2019 op de markt....tte tte te laat !!
Pharming gaat de HAE markt veroveren